Centessa Pharmaceuticals Analyst Ratings
Centessa Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 28.21% | Morgan Stanley | $4 → $8 | Upgrades | Underweight → Equal-Weight |
| 08/15/2023 | 76.28% | SVB Securities | $6 → $11 | Maintains | Outperform |
| 08/15/2023 | 60.26% | Guggenheim | $9 → $10 | Maintains | Buy |
| 08/15/2023 | -19.87% | Goldman Sachs | $4.5 → $5 | Maintains | Neutral |
| 07/25/2023 | 140.38% | BMO Capital | $11 → $15 | Maintains | Outperform |
| 06/21/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/12/2023 | 44.23% | Guggenheim | → $9 | Initiates Coverage On | → Buy |
| 05/15/2023 | -27.88% | Goldman Sachs | $4 → $4.5 | Maintains | Neutral |
| 03/17/2023 | -3.85% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 01/24/2023 | -35.9% | Morgan Stanley | $5 → $4 | Maintains | Underweight |
| 08/12/2022 | -19.87% | Morgan Stanley | $10 → $5 | Downgrades | Overweight → Underweight |
| 08/11/2022 | 76.28% | BMO Capital | $19 → $11 | Maintains | Outperform |
| 08/11/2022 | -35.9% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 07/15/2022 | 60.26% | Morgan Stanley | $15 → $10 | Maintains | Overweight |
| 06/17/2022 | 204.49% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 05/24/2022 | 140.38% | Morgan Stanley | $19 → $15 | Maintains | Overweight |
| 05/24/2022 | 28.21% | Goldman Sachs | $12 → $8 | Maintains | Neutral |
| 04/05/2022 | 204.49% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 06/23/2021 | 492.95% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 573.08% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
| 06/22/2021 | 492.95% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 460.9% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月26日 | 28.21% | 摩根士丹利 | $4→$8 | 升級 | 重量不足的→等重 |
| 2023年08月15日 | 76.28% | SVB證券 | $6→$11 | 維護 | 跑贏大盤 |
| 2023年08月15日 | 60.26% | 古根海姆 | $9→$10 | 維護 | 買 |
| 2023年08月15日 | -19.87% | 高盛 | $4.5→$5 | 維護 | 中性 |
| 07/25/2023 | 140.38% | 蒙特利爾銀行資本 | $11→$15 | 維護 | 跑贏大盤 |
| 2023年6月21日 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 2023/06/12 | 44.23% | 古根海姆 | →$9 | 開始承保 | →購買 |
| 2023年05月15日 | -27.88% | 高盛 | $4→$4.5 | 維護 | 中性 |
| 03/17/2023 | -3.85% | SVB Leerink | →$6 | 開始承保 | →跑贏大盤 |
| 01/24/2023 | -35.9% | 摩根士丹利 | $5→$4 | 維護 | 體重不足 |
| 2022年08月12日 | -19.87% | 摩根士丹利 | $10→$5 | 評級下調 | 增持→減持 |
| 2022年08月11日 | 76.28% | 蒙特利爾銀行資本 | $19→$11 | 維護 | 跑贏大盤 |
| 2022年08月11日 | -35.9% | 高盛 | $5→$4 | 維護 | 中性 |
| 07/15/2022 | 60.26% | 摩根士丹利 | $15→$10 | 維護 | 超重 |
| 06/17/2022 | 204.49% | 蒙特利爾銀行資本 | →$19 | 開始承保 | →跑贏大盤 |
| 2022年05月24日 | 140.38% | 摩根士丹利 | $19→$15 | 維護 | 超重 |
| 2022年05月24日 | 28.21% | 高盛 | $12→$8 | 維護 | 中性 |
| 04/05/2022 | 204.49% | 摩根士丹利 | $20→$19 | 維護 | 超重 |
| 2021/06/23 | 492.95% | 摩根士丹利 | →$37 | 開始承保 | →超重 |
| 2021/06/22 | 573.08% | 高盛 | →$42 | 開始承保 | →購買 |
| 2021/06/22 | 492.95% | 摩根士丹利 | →$37 | 開始承保 | →超重 |
| 2021/06/22 | 460.9% | 傑富瑞 | →$35 | 開始承保 | →購買 |
What is the target price for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的目標價是多少？
The latest price target for Centessa Pharmaceuticals (NASDAQ: CNTA) was reported by Morgan Stanley on October 26, 2023. The analyst firm set a price target for $8.00 expecting CNTA to rise to within 12 months (a possible 28.21% upside). 10 analyst firms have reported ratings in the last year.
摩根士丹利於2023年10月26日報道了森特薩製藥(納斯達克：CNTA)的最新目標價。這家分析公司將目標價定為8.00美元，預計CNTA將在12個月內上漲(可能上漲28.21%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的最新分析師評級是什麼？
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ: CNTA) was provided by Morgan Stanley, and Centessa Pharmaceuticals upgraded their equal-weight rating.
摩根士丹利提供了對森特薩製藥(納斯達克代碼：CNTA)的最新分析師評級，森特薩製藥上調了其同等權重評級。
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Centessa PharmPharmticals(CNTA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Centessa PharmPharmticals的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Centessa製藥的上一次評級是在2023年10月26日提交的，所以你應該預計下一次評級將在2024年10月26日左右的某個時候公佈。
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
分析師對Centessa PharmPharmticals(CNTA)的評級正確嗎？
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a upgraded with a price target of $4.00 to $8.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $6.24, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Centessa PharmPharmticals(CNTA)的最新評級被上調，目標價為4.00美元至8.00美元。Centessa PharmPharmticals(CNTA)目前的交易價格為6.24美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。